All
FDA Approves Rituxan Biosimilar to Treat Blood Cancers
July 23rd 2019The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
Cancer Survivors and Partial Remission: If Only We Could Freeze Time
July 18th 2019There are times in our cancer journey – and in life – when we want to “freeze time.” I am only in temporary remission, and eventually will have to go back on chemo again. This time it will likely be a new one with unknown consequences.